Blog
RSS FeedPosted by Michael Wonder on 11 Sep 2023
Act’s productivity perspective on PHARMAC medication and treatments will hurt minorities
11 September 2023 - Act is proposing a “productivity perspective based on real lives” when it comes to delivering PHARMAC ...
Posted by Michael Wonder on 10 Aug 2023
How a controversial US drug policy could be harming cancer patients worldwide
9 August 2023 - The FDA’s accelerated approval process was designed to help people access life saving drugs. ...
Posted by Michael Wonder on 08 Aug 2023
How industrial policy could accelerate innovation in the life sciences
8 August 2023 - The US is expanding public investment in the technology-based industries, including the life sciences, in a move ...
Posted by Michael Wonder on 17 Jul 2023
Novel Alzheimer disease treatments and reconsideration of US pharmaceutical reimbursement policy
17 July 2023 - While donanemab appears to be among the first therapies to demonstrate measurable clinical benefit for Alzheimer's disease, ...
Posted by Michael Wonder on 07 Jul 2023
A priority review voucher program to fuel generic drug development
6 July 2023 - Millions of Americans report that they are unable to fill their prescriptions or are not taking their ...
Posted by Michael Wonder on 28 Jun 2023
Korea’s drug pricing policies for the second half of 2023
22 June 2023 - In the first half of 2023, the Ministry of Health and Welfare set up a public ...
Posted by Michael Wonder on 10 Jun 2023
A review of labeling based on patient reported outcome endpoints for new oncology drugs approved by the EMA (2017-2021)
9 June 2023 - A review of new oncology indications approved by the EMA for 2012-2016 showed that 33% of new ...
Posted by Michael Wonder on 12 Apr 2023
ASCO policy statement on biosimilar and interchangeable products in oncology
12 April 2023 - Given the current market dynamics and the regulatory landscape, this ASCO manuscript now seeks to propose several ...
Posted by Michael Wonder on 11 Feb 2023
State of the Union highlights America’s awkward conversation on financing the development of new medicines
9 February 2023 - Science, medicine, health care, and paying for medicines featured prominently in President Joe Biden’s State of ...
Posted by Michael Wonder on 06 Feb 2023
Medical technology strategy
3 February 2023 - This document presents the inaugural UK medtech strategy and the timing could not be better. ...
Posted by Michael Wonder on 24 Jan 2023
Private insurance can contribute to a healthier system
24 January 2023 - Given what many describe as a crisis in primary care, it’s well past time to revisit the ...
Posted by Michael Wonder on 23 Jan 2023
Calls to allow private health insurance to cover fee gaps
24 January 2023 - Health funds are pushing to be able to cover doctors’ gap fees as part of national ...
Posted by Michael Wonder on 23 Jan 2023
China’s drug pricing policy impedes biotech profits
23 January 2023 - Beijing’s push to boost the sector has been undermined by reimbursement rules. ...
Posted by Michael Wonder on 11 Jan 2023
Prescription drug policy, 2022 and 2023: the year in review and the year ahead
9 January 2023 - This past year featured many significant developments in the prescription drug policy area, most notably the passage ...
Posted by Michael Wonder on 21 Dec 2022
Ontario expanding safe use of biosimilars
20 December 2022 - Transitioning to biosimilars will allow province to invest in and improve access to medicines. ...